Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University and the Oxford University Hospitals NHS Trust have partnered with Abide Therapeutics to explore the therapeutic potential of serine hydrolases, a relatively underexplored class of drug targets. The collaboration will support new target discovery with the goal of running several early phase clinical studies to demonstrate proof of biology and therapeutic opportunity in man.

Read more (Abide Therapeutics website)